Fatal congestive heart failure with deferiproneAQODAD, N; LOREAL, O; ERDTMAN, L et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 6-7, pp 656-657, issn 0399-8320, 2 p.Article

La chélation du fer en 1998 = Iron chelationDE MONTALEMBERT, M.Transfusion clinique et biologique (Paris). 1998, Vol 5, Num 5, pp 353-356, issn 1246-7820Article

The Fenton Activity of Iron(III) in the Presence of DeferiproneDEVANUR, Lakshmi D; NEUBERT, Hendrik; HIDER, Robert C et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 4, pp 1454-1467, issn 0022-3549, 14 p.Article

Influence of the chelator 1,2-dimethyl-3-hydroxypyrid-4-one on aluminum elimination in aluminum-loaded rabbitsXI, C; PING, L; WUSHIDE et al.Trace elements and electrolytes. 1997, Vol 14, Num 3, pp 130-133, issn 0946-2104Article

Oral Iron chelation therapy with Deferiprone in patients with Thalassemia MajorSAJID, Raihan; GHANI, Farooq; ADIL, Salman et al.Journal of the Pakistan Medical Association. 2009, Vol 59, Num 6, pp 388-390, issn 0030-9982, 3 p.Article

Regression of Symptoms After Selective Iron Chelation Therapy in a Case of Neurodegeneration with Brain Iron AccumulationLUCA FOMI, Gian; BALOCCO, Manuela; CREMONESI, Laura et al.Movement disorders. 2008, Vol 23, Num 6, pp 905-908, issn 0885-3185, 4 p.Article

Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patientsMAGGIO, Aurelio; VITRANO, Angela; GERARDI, Calogera et al.American journal of hematology. 2012, Vol 87, Num 7, pp 732-733, issn 0361-8609, 2 p.Article

Chelating Agents for the Treatment of Systemic Iron OverloadMA, Y; ZHOU, T; KONG, X et al.Current medicinal chemistry. 2012, Vol 19, Num 17, pp 2816-2827, issn 0929-8673, 12 p.Article

Surcharge en fer d'origine hématologique = Post-transfusional iron overload, iron loading anemiaROSE, C.La Revue de médecine interne (Paris). 2012, Vol 33, issn 0248-8663, S15-S18, SUP1Conference Paper

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imagingPEPE, Alessia; MELONI, Antonella; FILOSA, Aldo et al.Haematologica (Roma). 2011, Vol 96, Num 1, pp 41-47, issn 0390-6078, 7 p.Article

Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent DevelopmentsLEITCH, Heather A.Drugs (Basel). 2011, Vol 71, Num 2, pp 155-177, issn 0012-6667, 23 p.Article

Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron OverloadLIU, Joe; OBANDO, Daniel; SCHIPANSKI, Liam G et al.Journal of medicinal chemistry (Print). 2010, Vol 53, Num 3, pp 1370-1382, issn 0022-2623, 13 p.Article

Aspects épidémiologiques et économiques des traitements chélateurs au centre thérapeutique de la thalassémie au Maroc = Epidemiological and economic aspects of chelating therapy in the therapeutic center of thalassemia in MoroccoAGOUZAL, M; QUYOU, A; BENCHEKROUNE, K et al.Revue médicale de Bruxelles. 2010, Vol 31, Num 2, pp 79-87, issn 0035-3639, 9 p.Article

Traitement des surcharges en fer : place du déférasirox, nouveau chélateur oral du fer = Treatment of iron overload : usefulness of deferasirox, a new oral chelator of ironLAINE, F; DEUGNIER, Y.La Lettre du pharmacologue (Boulogne). 2007, Vol 21, Num 3, pp 68-72, issn 0984-452X, 5 p.Article

Survival of medically treated thalassemia patients in Cyprus. Trends and risk factors over the period 1980-2004TELFER, Paul; COEN, Pietro G; SITAROU, Maria et al.Haematologica (Roma). 2006, Vol 91, Num 9, pp 1187-1192, issn 0390-6078, 6 p.Article

Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic childrenGOMBER, Sunil; SAXENA, Rohit; MADAN, Nishi et al.Indian pediatrics. 2004, Vol 41, Num 1, pp 21-27, issn 0019-6061, 7 p.Article

Benefits and risks of deferiprone in iron overload in thalassaemia and other conditions: Comparison of epidemiological and therapeutic aspects with deferoxamineKONTOGHIORGHES, George J; NEOCLEOUS, Katia; KOLNAGOU, Annita et al.Drug safety. 2003, Vol 26, Num 8, pp 553-584, issn 0114-5916, 32 p.Article

The combined effects of the chelating agent deferiprone, ascorbic acid and mesna on urinary aluminum excretion in rabbitsPING, L; XI, C; SHIDE, W et al.Trace elements and electrolytes. 2003, Vol 20, Num 2, pp 79-82, issn 0946-2104, 4 p.Article

Effects on Mycobacterium avium replication in normal human macrophages by deferiprone (L1) and other Iron chelators possible implications on toxicityDOUVAS, George S; MAY, Mary H; KOLNAGOU, Annita et al.Arzneimittel-Forschung. 2002, Vol 52, Num 1, pp 45-52, issn 0004-4172Article

Orally active iron chelatorsMERSON, L; OLIVIERI, N.Blood reviews. 2002, Vol 16, Num 2, pp 127-134, issn 0268-960XArticle

Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemiaWANLESS, Ian R; SWEENEY, George; DHILLON, Amar P et al.Blood. 2002, Vol 100, Num 5, pp 1566-1569, issn 0006-4971, 4 p.Article

The controversial role of deferiprone in the treatment of thalassemiaRICHARDSON, Des R.The Journal of laboratory and clinical medicine. 2001, Vol 137, Num 5, pp 324-329, issn 0022-2143Article

Deferiprone : A review of its clinical potential in iron overload in β-thalassaemia major and other transfusion-dependent diseasesBALFOUR, J. A. B; FOSTER, R. H.Drugs (Basel). 1999, Vol 58, Num 3, pp 553-578, issn 0012-6667Article

Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamineTAHER, A; CHAMOUN, F. M; KOUSSA, S et al.Acta haematologica. 1999, Vol 101, Num 4, pp 173-177, issn 0001-5792Article

Annotation : Oral deferiprone - controversies on its efficacy and safety : Symposium : Hematology/Oncology : Part IICHOUDHRY, V. P.Indian journal of pediatrics. 1998, Vol 65, Num 6, pp 825-828, issn 0019-5456Article